PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 74.77

Change

+0.98 (+1.33)%

Market Cap

N/A

Volume

0.22M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.09 (+0.05%)

USD 85.62B
RDY Dr. Reddy’s Laboratories Ltd..

-59.38 (-80.25%)

USD 63.63B
TAK Takeda Pharmaceutical Co Ltd A..

+0.17 (+1.21%)

USD 44.45B
HLN Haleon plc

+0.01 (+0.10%)

USD 43.99B
CTLT Catalent Inc

-0.21 (-0.36%)

USD 10.78B
ELAN Elanco Animal Health

+0.11 (+0.88%)

USD 6.18B
BHC Bausch Health Companies Inc

+0.43 (+4.64%)

USD 3.56B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.16 (-1.90%)

USD 2.55B
CPHI China Pharma Holdings Inc

-0.01 (-3.80%)

USD 4.03M
YCBD cbdMD Inc

-0.01 (-2.17%)

USD 2.11M

ETFs Containing PBH

NDIA Global X Funds 3.47 % 0.00 %

+0.41 (+1.36%)

USD 0.03B
XST:CA iShares S&P/TSX Capped Co.. 3.17 % 0.61 %

+0.70 (+1.36%)

CAD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.13% 67% D+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.13% 67% D+ 80% B-
Trailing 12 Months  
Capital Gain 24.87% 60% D- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.87% 60% D- 68% D+
Trailing 5 Years  
Capital Gain 96.45% 93% A 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 96.45% 93% A 84% B
Average Annual (5 Year Horizon)  
Capital Gain 16.63% 87% B+ 79% B-
Dividend Return 16.63% 87% B+ 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.10% 73% C 51% F
Risk Adjusted Return 78.82% 100% F 89% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector